Cost-effectiveness of biologics in early rheumatoid arthritis

Annals of Internal Medicine

Volumn 152, Issue 5, 2010, Pages 333-334

  Finckh, Axel ^a   Bansback, Nick ^b   Liang, Matthew H ^c  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; NONSTEROID ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; IMMUNOLOGIC FACTOR;

COST EFFECTIVENESS ANALYSIS; DISABILITY; DISEASE PREDISPOSITION; DRUG EFFICACY; EARLY DIAGNOSIS; GLUCOSE INTOLERANCE; HUMAN; HYPERTENSION; INFECTION; JOINT PROSTHESIS; LETTER; MORTALITY; OBESITY; OSTEOPOROSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; TREATMENT DURATION; COST BENEFIT ANALYSIS; ECONOMICS; NOTE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; HUMANS; IMMUNOLOGIC FACTORS;

EID: 77950357873     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-152-5-201003020-00018     Document Type: Letter

References (4)

1. Boers M. Cost-effectiveness of biologics as first-line treatment of rheumatoid arthritis: case closed? [Editorial]. Ann Intern Med. 2009;151:668-669 [PMID: 19884628]
2. Finckh A, Bansback N, Marra CA, Anis AH, Michaud K, Lubin S, et al. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis. Ann Intern Med. 2009;151:612-621 [PMID: 19884622]
3. Da Silva JA, Jacobs JW, Kirwan JR, Boers M, Saag KG, Inês LB, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006;65:285-293 [PMID: 16107513]
4. Maillefert JF. Appropriate and inappropriate use of oral glucocorticoid therapy in rheumatoid arthritis [Editorial]. Joint Bone Spine. 2006;73:234-235 [PMID: 16563844]